Incyte Valuation
Is INCY * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of INCY * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: INCY * (MX$986) is trading below our estimate of fair value (MX$3288.76)
Significantly Below Fair Value: INCY * is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for INCY *?
Other financial metrics that can be useful for relative valuation.
What is INCY *'s n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | US$11.60b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 2.2x |
Enterprise Value/EBITDA | 10.8x |
PEG Ratio | 1x |
Price to Earnings Ratio vs Peers
How does INCY *'s PE Ratio compare to its peers?
Company | Forward PE | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 46.3x | ||
UTHR United Therapeutics | 11.2x | 7.6% | US$11.0b |
BMRN BioMarin Pharmaceutical | 74.8x | 29.6% | US$15.4b |
SOBI Swedish Orphan Biovitrum | 44.6x | 24.8% | kr95.5b |
NBIX Neurocrine Biosciences | 54.8x | 26.9% | US$13.7b |
INCY * Incyte | 19.4x | 18.8% | Mex$11.6b |
Price-To-Earnings vs Peers: INCY * is good value based on its Price-To-Earnings Ratio (19.4x) compared to the peer average (46.3x).
Price to Earnings Ratio vs Industry
How does INCY *'s PE Ratio compare vs other companies in the Global Biotechs Industry?
Price-To-Earnings vs Industry: INCY * is good value based on its Price-To-Earnings Ratio (19.4x) compared to the Global Biotechs industry average (30.2x).
Price to Earnings Ratio vs Fair Ratio
What is INCY *'s PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PE Ratio | 19.4x |
Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate INCY *'s Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.